Comparison of Infinity Pharmaceuticals Inc. (INFI) and Pain Therapeutics Inc. (NASDAQ:PTIE)

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Pain Therapeutics Inc. (NASDAQ:PTIE) compete with each other in the Biotechnology sector. We will analyze and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Infinity Pharmaceuticals Inc. 22.15M 4.62 11.25M 1.25 1.28
Pain Therapeutics Inc. N/A 0.00 8.30M -1.16 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Infinity Pharmaceuticals Inc. and Pain Therapeutics Inc.

Profitability

Table 2 represents Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Pain Therapeutics Inc. (NASDAQ:PTIE)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals Inc. -50.79% -20.8% -18.2%
Pain Therapeutics Inc. 0.00% -68.4% -63.1%

Risk & Volatility

Infinity Pharmaceuticals Inc.’s 2.22 beta indicates that its volatility is 122.00% more volatile than that of Standard and Poor’s 500. Pain Therapeutics Inc.’s 94.00% more volatile than Standard and Poor’s 500 which is a result of the 1.94 beta.

Liquidity

Infinity Pharmaceuticals Inc.’s Current Ratio is 10.7 while its Quick Ratio is 10.7. On the competitive side is, Pain Therapeutics Inc. which has a 24 Current Ratio and a 24 Quick Ratio. Pain Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Infinity Pharmaceuticals Inc.

Analyst Recommendations

The Ratings and Recommendations for Infinity Pharmaceuticals Inc. and Pain Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Infinity Pharmaceuticals Inc. 1 1 1 2.33
Pain Therapeutics Inc. 0 0 0 0.00

Infinity Pharmaceuticals Inc. has a 66.67% upside potential and an average price target of $3.

Insider and Institutional Ownership

The shares of both Infinity Pharmaceuticals Inc. and Pain Therapeutics Inc. are owned by institutional investors at 54.9% and 24.4% respectively. Insiders held 1.1% of Infinity Pharmaceuticals Inc. shares. Comparatively, Pain Therapeutics Inc. has 0.9% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Infinity Pharmaceuticals Inc. -3.03% 32.23% 16.79% -21.57% -16.67% 35.59%
Pain Therapeutics Inc. -1.64% 2.56% 8.11% 22.45% -81.54% 41.18%

For the past year Infinity Pharmaceuticals Inc. was less bullish than Pain Therapeutics Inc.

Summary

Infinity Pharmaceuticals Inc. beats Pain Therapeutics Inc. on 7 of the 11 factors.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The companyÂ’s lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat AlzheimerÂ’s disease and other neurological disorders. The company was founded in 1998 and is based in Austin, Texas.